L2M- Assessing the commercial landscape of an at-home fertility treatment platform

Infertility affects 15% of couples in the U.S. and Canada, with 20-50% of cases linked to male factors. Current treatments like Intra-Uterine Insemination (IUI) are costly, invasive, and have low success rates (5-15% per round), creating significant barriers for couples. Fertilead Inc. addresses these challenges with FertilEZ, a self-administered at-home fertility kit that improves sperm separation compared to clinic methods, offering a more affordable, accessible, and private solution for male infertility treatment. Backed by patented technology developed through advanced research, FertilEZ aims to empower couples to take control of their fertility journey. To support commercialization, Fertilead is building a regulatory roadmap for approvals in Canada and the US and evaluating a B2C direct-to-consumer model alongside B2B partnerships with fertility clinics. By combining scientific innovation with accessibility, Fertilead seeks to transform fertility care for couples worldwide.

Faculty Supervisor:

Virgilio Valente

Student:

Partner:

I-INC Foundation for Business Development

Discipline:

Engineering

Sector:

Professional, scientific and technical services

University:

Toronto Metropolitan University

Program: